HMGB1 and melanoma: One study found that using stattic, a STAT3 inhibitor, in combination with the chemotherapeutic and known ICD-inducer doxorubicin, leads to increased ecto-CRT, increased release of HMGB1, and increased expression of 70-kilodalton heat shock proteins (HSP70) [61], suggesting that STAT3 is a potential target for the induction of melanoma ICD.